Comparison of Obturator Nerve Block With Ultrasound Guidance and Anatomical Signs

Sponsor
Muğla Sıtkı Koçman University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04638569
Collaborator
(none)
116
1
2
18.5
6.3

Study Details

Study Description

Brief Summary

Comparison of the obturator nerve block in patients undergoing transurethral resection due to bladder tumor, technically using ultrasound guided or blinded with anatomical signs.

Condition or Disease Intervention/Treatment Phase
  • Procedure: obturator nerve block
N/A

Detailed Description

The primary aim of this study is to compare the success rates of ONB techniques performed with ultrasound guided or blind technique. Its secondary purpose is to compare the effect of peroperative bleeding and control cystoscopy performed in the postoperative 3rd month on the presence of recurrent tumor.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
116 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
group 1; Ultrasound-guided obturator nerve block group 2; obturator nerve block with anatomical signsgroup 1; Ultrasound-guided obturator nerve block group 2; obturator nerve block with anatomical signs
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Comparison of Obturator Nerve Block With Ultrasound Guidance and Anatomical Signs in Patients Undergoing Transurethral Resection
Actual Study Start Date :
Feb 16, 2021
Anticipated Primary Completion Date :
Mar 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Ultrasound-guided obturator nerve block group

The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle.

Procedure: obturator nerve block
The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.

Active Comparator: obtutaror nerve block with anatomical landmarks

In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL.

Procedure: obturator nerve block
The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.

Outcome Measures

Primary Outcome Measures

  1. Preoperative succesful obturator nerve block [operation time]

    peroperative adductor muscle spazm

Secondary Outcome Measures

  1. peroperative bleeding, Presence of recurrent tumor at postoperative 3rd month [3 months]

    peroperative bledding, Control by cystoscopy in the postoperative 3rd month recurrence tumor size

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ASA I-II patients
Exclusion Criteria:
  • Tumors that disrupt the integrity of the bladder,

  • bladder floor tumors,

  • coagulation disorders,

  • motor in the lower limbs

  • with sensory disturbances,

  • uncooperative patients,

  • Known allergy to local anesthetics

  • patients with localized infection at the procedure site

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mugla Sitki Kocman University Mugla Turkey 48000

Sponsors and Collaborators

  • Muğla Sıtkı Koçman University

Investigators

  • Principal Investigator: Eylem Yaşar, Muğla Sıtkı Koçman University
  • Study Chair: Ali İhsan Uysal, Mugla Sitki Kocman University Department of Anesthesia
  • Study Chair: İlker Akarken, Mugla Sitki Kocman University Department of Urology
  • Study Chair: basak altiparmak, Mugla Sitki Kocman University Department of Anesthesia
  • Study Chair: semra demirbilek, Mugla Sitki Kocman University Department of Anesthesia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eylem Yaşar, medical doctor of anesthesiology special, Muğla Sıtkı Koçman University
ClinicalTrials.gov Identifier:
NCT04638569
Other Study ID Numbers:
  • 27/12/2019-19/VIII
First Posted:
Nov 20, 2020
Last Update Posted:
Feb 7, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Eylem Yaşar, medical doctor of anesthesiology special, Muğla Sıtkı Koçman University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 7, 2022